For years, Cytelligen and Cytointelligen have been working closely with doctors and research professionals in U.S. and China on clinical and translational technologies relating to Enumeration of circulating tumor cells (CTCs). Circulating tumor cells (CTCs) are tumor cells released from the primary tumor mass into peripheral blood. Following circulating in blood, some of CTCs are apoptotic, and some of those survived CTCs may reach a target organ and attach to the endothelial cell. After invading the endothelium, a secondary tumor mass will develop. The similar process is shared by cancer relapse. Cytelligen has developed an unique integrated platform of subtraction enrichment (SE) and immunostaining-FISH (iFISH) to efficiently detect circulating rare cells, including CTC shed from various epithelial solid tumors, circulating endothelial cell (CEC), and stem cell, etc.. The SE-iFISH technology is widely used for its uniqueness and precision on detecting tumor cells as well as related translational researches which has granted international recognition by international journal such as Science (Science 2013,341:415).
This discussion will provide an understanding of the SE-iFISH technology by Cytelligen and Cytointelligen and the various application of the SE-iFISH technology on cancer diagnostics, which might cover,
1. introduction to the subtraction enrichment (SE) and immunostaining-FISH (iFISH) SE-iFISH technology
2. Explore the Cytelligen Integrated Platform to Isolate, Detect and Analyze CTC
3. Discussion with fellows in Hong Kong
We aim to provide participants with understanding of the SE-iFISH technology and opportunity for potential collaboration.
Objective
To explore and discuss the possibility in terms of clinical and biomedical research application of detecting circulating tumor cells via the unique SE-iFISH platform in Hong Kong.
Cytelligen is located in San Diego, California, USA. Cytelligen's subsidiary facility - Cytointelligen is in China Medical City, Taizhou, Jiangsu, China.
Cytelligen and Cytointelligen, the inventor of SE-iFISH technology, hold patents and trade marsk relative to enrichment and identification of circulating tumor cells. This technology has been validated on over 3000 thousands clinical samples of various cancer patients.
